To Evaluate the Effects of EryDex in Patients With A-T

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangectasia (A-T).
Epistemonikos ID: c5b57a9d2d3808e9bcc291d270c618244a38a1fb
First added on: May 15, 2024